Vaccinex, Inc. · OTC:VCNX
Vaccinex — Corporate Update (June 2022)
16 slides from Vaccinex's corporate update, Jun 10, 2022
Slide 1: KEYNOTE-B84 Study in HNSCC
KEYNOTE-B84 Study in HNSCC June 10, 2022 Pepinemab – Anti-SEMA4D Antibody for Cancer Immunotherapy Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Such statements
Slide 3: Why Does Immune Response Fail in Tumors?
WHY DOES IMMUNE RESPONSE FAIL IN TUMORS? Sema4D is expressed at tumor margin Sema4D binds PLXN receptors on DCs and restricts penetration T-cells are excluded from tumor Pro-inflammatory cells are excluded from tumor and build up at the invasive edge CD8 T cells align with Sema4D at the invasive edg
Slide 4: Unique Mechanism
UNIQUE MECHANISM No treatment Low CD8+ T cells High Tumor content and MDSC Pepinemab High CD8+ T cells Low tumor content and MDSC Biopsies from patients with metastatic MSS Colorectal Cancer Human metastatic colorectal tumor, in collaboration with Winship Cancer Institute, Emory University integrate
Slide 5: Rationale for Treatment of HNSCC
RATIONALE FOR TREATMENT OF HNSCC Head and Neck cancer (HNSCC) Data suggest that SEMA4D is strongly expressed in HNSCC & induces high levels of myeloid derived suppressor cells (MDSC) Relatively low (17-19%) response rate to immune checkpoint therapy in HNSCC NSCLC HNSCC MDSC Density NSCLC vs HNSCC H
Slide 6: KEYNOTE B84 Head and Neck Cancer Trial
Topline Data Objective Response JUL 2021 JAN 2022 2H 2022 2H 2023 Interim Report ~midpoint of enrollment ~ November ‘22 Safety Period KEYNOTE B84 HEAD AND NECK CANCER TRIAL All patients receive standard of care Keytruda®, plus pepinemab for first- line treatment Ph1b Safety: COMPLETE Appeared to be
Slide 7: KEYNOTE-B84: Case studies to illustrate differences in positive response profiles
KEYNOTE-B84: Case studies to illustrate differences in positive response profiles Left Lung Right Lung Pre-treatment 9 weeks 15 weeks Adverse Events Pre-treatment 9 weeks 15 weeks Biomarkers PD-L1 CPS<20 HPV negative 19% decrease, SD 100% decrease, CR Confirmed, CR Now 42 Weeks week 5 week 9 week 15
Slide 8: KEYNOTE-B84 Trial Sites
Fresno, CA California Cancer Associates for Research and Excellence Steven Hager San Francisco, CA UCSF Medical Center at Mission Bay Alain Algazi Celebration, FL Advent Health Celebration George Simon Orlando, FL Advent Health Orlando Tarek Mekhail Canton, OH Gabrail Cancer Research Center Nashat G
Slide 9: Pepinemab – Anti-SEMA4D Antibody for Huntington's and Alzheimer's Disease
Pepinemab – Anti-SEMA4D Antibody for Huntington’s and Alzheimer’s Disease Unique Targets Novel Mechanisms New Medicines
Slide 10: SEMA4D Is Upregulated in Neurons During Alzheimer's and Huntington's Disease Progression
SEMA4D IS UPREGULATED IN NEURONS DURING ALZHEIMER’S AND HUNTINGTON’S DISEASE PROGRESSION Human autopsy sections of frontal lobe Huntington’s Disease Normal Alzheimer’s Disease Human autopsy sections of frontal lobe Sema4D Neuron (HUC/HUD) Semaphorin 4D is upregulated in neurons of diseased brains an
Slide 11: Cognitive Assessment Battery (HD-CAB) Co-Primary and Exploratory Analysis
LS Mean Difference Estimate (95% CI) One-sided p-value Favors Pepinemab Critical value 0.13 (0.03, 0.23) 0.007 Yes Yes [0.025] HD-CAB Composite Index: Pre-specified Exploratory Two-item HD Cognitive Assessment: Pre-specified Co-Primary COGNITIVE ASSESSMENT BATTERY (HD-CAB) Co-Primary and pre-specifi
Slide 12: Cognitive Assessment Battery (HD-CAB) Exploratory and Post-hoc Analysis
COGNITIVE ASSESSMENT BATTERY (HD-CAB) Exploratory and Post-hoc analysis p=0.007 p=0.0025 pepinemab placebo pepinemab placebo prodromal early manifest Pepinemab antibody blockade of SEMA4D in early Huntington’s Disease: the randomized, placebo-controlled, phase 2 SIGNAL trial Andrew Feigin, Elizabeth
Slide 13: Alzheimer's Disease Phase 1b/2 Trial Design
ALZHEIMER’S DISEASE Phase 1b/2 Trial Design n=20 placebo Monthly X12 months Safety Follow-up n=20 pepinemab Monthly 40 mg/kg X12 months Safety Follow-up 2H 2023 Data Safety Monitoring Board meeting - Complete, Feb 2022 Funding by Topline Data Randomized 1:1 Double-blind Phase 1b: Safety n=4 JUL 2021
Slide 14: Signal-AD Site Map
San Diego, CA Pacific Research Network, Inc Stephen Thein Dixie Creager Signal-AD Site Map Delray Beach, FL Brain Matters Research Mark Brody Jennifer Blasi Stuart, FL Brain Matters Research-Satellite Site Mark Brody Jennifer Blasi Rochester, NY University of Rochester Anton Porsteinsson Asa Widman
Slide 15: Vaccinex, Inc. company overview
Vaccinex, Inc. (Nasdaq: VCNX) is a publicly traded clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases with unmet medical needs, including cancer and neurodegenerative diseases. INCORPORATED 2001 HEADQUARTERS Rochester,
Slide 16: Pipeline and Milestones
Research/Preclinical Research/Preclinical Phase 1 Phase 2 Phase 3 Partner/Funding Milestone Pepinemab Antibody Platform (anti-Semaphorin 4D Mab) Oncology Complete, Published 2021 Ongoing Next data 2H 2022 Neurology Complete, Nat. Med in press Ongoing Data 2H 2023 Pepinemab COMBO with Pembrolizumab i